Enhanced Expression of Podoplanin in Oral Carcinomas in situ and Squamous Cell Carcinomas
Objective: Podoplanin, a known lymphatic endothelial cell marker, has been reported to be expressed in various types of cancer. To elucidate the expression of podoplanin in precancerous lesions, we examined the immunohistochemical profiles of podoplanin in oral squamous epithelial lesions. Method: W...
Saved in:
Main Authors: | , , , , , , , , , |
---|---|
Format: | Academic Paper |
Published: |
Pathobiology,
2022-04-25T02:59:53Z.
|
Subjects: | |
Online Access: | Get Fulltext |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Objective: Podoplanin, a known lymphatic endothelial cell marker, has been reported to be expressed in various types of cancer. To elucidate the expression of podoplanin in precancerous lesions, we examined the immunohistochemical profiles of podoplanin in oral squamous epithelial lesions. Method: We studied a total of 298 foci of squamous cell carcinoma (SCC), carcinoma in situ (CIS), epithelial dysplasia, and hyperplastic and/or normal epithelial lesions by immunohistochemistry using D2-40. Results: There was no positivity for podoplanin in normal or hyperplastic epithelia, while all of the CIS and SCC foci stained positive. Approximately one third of the mild dysplasia foci (10 of 36 foci, 28%) and 80% of moderate dysplasia foci (78/98) showed grade 1 positive reactions (positive only in the 1st layer). Grade 2 reactions (up to 4th layer) were seen in 4 of 98 moderate dysplasia foci (4%), 29 of 74 CIS foci (39%), and 3 of 30 SCC foci (10%). Grade 3 reactions (to more than 5th layer) were found in 35 (47%) CIS foci and 26 (87%) SCC foci. Conclusions: The relationship between the present histological categorization and podoplanin grade was statistically significant. D2- 40 expression is considered to be related to the severity of oral precancerous lesions. |
---|---|
Item Description: | Kodeprodi#1610101#KedokteranGigi NIDN#0029056802 http://repository.unej.ac.id/xmlui/handle/123456789/106573 |